Replies to post #115814 on Amarin Corp Plc (AMRN)

[HDGabor]

sts-

I don't recall in the BD's about the mineral oil group and any other biomarkers except for TGs

Well, from the BD:

5.2 Secondary Endpoint Results

Median LDL-C increased from baseline to Week 12 in all treatment groups despite stable statin therapy, with the placebo group exhibiting the largest increase ... Median non-HDL-C levels increased from baseline to Week 12 in the placebo and AMR101 2g groups and decreased by 5% in the AMR101 4g group ... Also, note that for each of these parameters, with the exception of HDL-C and apo A1, the placebo group demonstrated nominally statistically significant changes from baseline in an adverse direction, while on background statin therapy.

See Table 18 on Page 41 of 94

the BS screwed up x-axis scale from the BD's they used to claim something weird happened with TGs in the drug vs. placebo group

I could not stand further :-) Nothing wrong with this scale ... I LMAO (anno) due to the fury on the board about this chart ... the answer is very simple ... the meaning (scale) of the x-axis:

Screening (Visit 1/Week -8 or Week -6) ... Visit 2 (Week -2) and Visit 3 (Week -1) ... Randomization Visit (Week 0) ... Post-Randomization Follow-up (Visit 5/Week 4, Visit 6/Week 11), Week 12 endpoint

as the study was designed ...

Best,
G